Ronald Martell
Chief Executive Officer at JASPER THERAPEUTICS, INC.
Net worth: 972 374 $ as of 2024-03-30
Profile
Ronald A.
Martell is the founder of Orca Biosystems, Inc. (founded in 2016) and Indapta Therapeutics, Inc. (founded in 2017) where he holds the title of Executive Chairman.
Mr. Martell was also the founder of Cetya Therapeutics, Inc., Encellin, Inc., and Achieve Life Science, Inc. Mr. Martell's current job(s) included being the President, Chief Executive Officer & Director at Jasper Therapeutics, Inc. since 2022, and an Independent Director at MorphImmune, Inc. since 2021.
Mr. Martell's former job(s) include being the Chairman & Chief Executive Officer at Poniard Pharmaceuticals, Inc. in 2012, President, Chief Executive Officer & Director at Sevion Therapeutics, Inc. from 2014 to 2015, President, Chief Executive Officer & Director at NeurogesX, Inc. from 2012 to 2013, President, Chief Executive Officer & Director at Nuvelution Pharma, Inc. from 2019 to 2021, Executive Chairman at Humanigen, Inc. in 2015, Executive Chairman at Kalobios Pharmaceuticals, Inc. in 2015, Independent Director at Plus Therapeutics, Inc. from 2016 to 2019, and Group Manager-Oncology Products at Genentech, Inc. from 1988 to 1998.
He also served as Senior Vice President-Commercial Operations at ImClone LLC from 1998 to 2006.
Mr. Martell is also the founder of Cetya Therapeutics, Inc., Encellin, Inc., and Achieve Life Science, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-14 | 33,119 ( 0.22% ) | 972 374 $ | 2024-03-30 |
Ronald Martell active positions
| Companies | Position | Start |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Chief Executive Officer | 2022-03-14 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Founder | 2016-12-31 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Director/Board Member | - |
Former positions of Ronald Martell
| Companies | Position | End |
|---|---|---|
Nuvelution Pharma, Inc.
 Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | Chief Executive Officer | 2021-02-28 |
| PLUS THERAPEUTICS, INC. | Director/Board Member | 2019-12-20 |
| HUMANIGEN, INC. | Chairman | 2015-11-19 |
| Kalobios Pharmaceuticals, Inc. | Chairman | 2015-09-30 |
Sevion Therapeutics, Inc.
 Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | Chief Executive Officer | 2015-01-07 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| PLUS THERAPEUTICS, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Sevion Therapeutics, Inc.
Sevion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sevion Therapeutics, Inc. operates as Biopharmaceutical Company. It discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company was founded on September 30, 1999 and is headquartered in San Diego, CA. | Commercial Services |
NeurogesX, Inc.
 NeurogesX, Inc. Pharmaceuticals: MajorHealth Technology NeurogesX, Inc. developed and commercialized novel pain management therapies. The company was founded by Wendye R. Robbins on May 28, 1998 and was headquartered in San Mateo, CA. | Health Technology |
Cetya Therapeutics, Inc.
 Cetya Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cetya Therapeutics, Inc. engages in the commercialization of histone deacetylase inhibitors based on largazole. Its histone deacetylase inhibitors analog has bifunctional modifications and the potential to target specific cell types or tumors. The company was founded by John Pilon in 2012 and is headquartered in Fort Collins, Co. | Health Technology |
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | Health Technology |
Achieve Life Science, Inc.
 Achieve Life Science, Inc. Pharmaceuticals: MajorHealth Technology Achieve Life Science, Inc. manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. The company was founded on August 10, 2015 and is headquartered in Mill Valley, CA. | Health Technology |
Orca Biosystems, Inc.
 Orca Biosystems, Inc. Medical SpecialtiesHealth Technology Orca Biosystems, Inc. engages in empowering cell therapies by precisely engineering bone marrow transplants (BMT) using rapid clinical cell sorting of human grafts. The company was founded by Nathaniel fernhoff and Ivan K. Dimov and is headquartered in Mountain View, CA. | Health Technology |
Encellin, Inc.
 Encellin, Inc. Medical SpecialtiesHealth Technology Encellin, Inc. provides transplant to address chronic diseases. It focuses on type 1 diabetes. The company was founded by Grace Wei, Ronald Martell, and Crystal Nyitray and is headquartered in San Francisco, CA. | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
| Jasper Therapeutics, Inc. | |
| Kalobios Pharmaceuticals, Inc. |
- Stock Market
- Insiders
- Ronald Martell
